Reference:
1. Reid BM, Permuth JB, Sellers TAJCb, medicine. Epidemiology of ovarian
cancer: a review. 2017;14(1):9.
2. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD,
et al. Ovarian cancer statistics, 2018. 2018;68(4):284-96.
3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal
AJCacjfc. Global cancer statistics 2018: GLOBOCAN estimates of incidence
and mortality worldwide for 36 cancers in 185 countries.
2018;68(6):394-424.
4. Du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E,
Bookman M, et al. 2004 consensus statements on the management of ovarian
cancer: final document of the 3rd International Gynecologic Cancer
Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).
2005;16(suppl_8):viii7-viii12.
5. Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K,
Berchuck A, et al. NCCN Guidelines Insights: Ovarian Cancer, Version
1.2019: Featured Updates to the NCCN Guidelines. 2019;17(8):896-909.
6. Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL,
et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian
cancer: Society of Gynecologic Oncology and American Society of Clinical
Oncology clinical practice guideline. 2016;143(1):3-15.
7. Negishi H, Takeda M, Fujimoto T, Todo Y, Ebina Y, Watari H, et al.
Lymphatic mapping and sentinel node identification as related to the
primary sites of lymph node metastasis in early stage ovarian cancer.
2004;94(1):161-6.
8. Dell’Anna T, Signorelli M, Benedetti-Panici P, Maggioni A, Fossati R,
Fruscio R, et al. Systematic lymphadenectomy in ovarian cancer at
second-look surgery: a randomised clinical trial. 2012;107(5):785-92.
9. Fagotti A, De Iaco P, Fanfani F, Vizzielli G, Perelli F, Pozzati F,
et al. Systematic Pelvic and Aortic Lymphadenectomy in Advanced Ovarian
Cancer Patients at the Time of Interval Debulking Surgery: A
Double-Institution Case–Control Study. 2012;19(11):3522-7.
10. Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, et al.
A randomized trial of lymphadenectomy in patients with advanced ovarian
neoplasms. 2019;380(9):822-32.
11. Beesley V, Janda M, Eakin E, Obermair A, Battistutta DJC. Lymphedema
after gynecological cancer treatment: prevalence, correlates, and
supportive care needs. 2007;109(12):2607-14.
12. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ WV.
Cochrane Handbook for Systematic Reviews of Interventions. Available
from: www.training.cochrane.org/handbook. .
13. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance
from the median , range , and the size of a sample. 2005;10:1–10. .
14. Song N, Gao YJIJoGC. Therapeutic value of selective lymphadenectomy
in interval debulking surgery for stage IIIc and IV epithelial ovarian
cancer. 2019;29(4):761-7.
15. Eoh KJ, Yoon JW, Lee I, Lee JY, Kim S, Kim SW, et al. The efficacy
of systematic lymph node dissection in advanced epithelial ovarian
cancer during interval debulking surgery performed after neoadjuvant
chemotherapy. 2017;116(3):329-36.
16. Eoh KJ, Lee J-Y, Yoon JW, Nam EJ, Kim S, Kim S-W, et al. Role of
systematic lymphadenectomy as part of primary debulking surgery for
optimally cytoreduced advanced ovarian cancer: Reappraisal in the era of
radical surgery. 2017;8(23):37807.
17. Salgado-Ceballos I, Ríos J, Pérez-Montiel D, Gallardo L,
Barquet-Muñoz S, Salcedo-Hernández R, et al. Is lymphadenectomy
necessary in mucinous ovarian cancer? A single institution experience.
2017;41:1-5.
18. Paik ES, Shim M, Choi HJ, Lee Y-Y, Kim T-J, Lee J-W, et al. Impact
of lymphadenectomy on survival after recurrence in patients with
advanced ovarian cancer without suspected lymph node metastasis.
2016;143(2):252-7.
19. Iwase H, Takada T, Iitsuka C, Nomura H, Abe A, Taniguchi T, et al.
Clinical significance of systematic retroperitoneal lymphadenectomy
during interval debulking surgery in advanced ovarian cancer patients.
2015;26(4):303-10.
20. Schwartz L, Schrot-Sanyan S, Brigand C, Baldauf J-J, Wattiez A,
Akladios CJAr. Impact of pelvic and para-aortic lymphadenectomy in
advanced ovarian cancer after neoadjuvant chemotherapy.
2015;35(10):5503-9.
21. Oshita T, Itamochi H, Nishimura R, Numa F, Takehara K, Hiura M, et
al. Clinical impact of systematic pelvic and para-aortic lymphadenectomy
for pT1 and pT2 ovarian cancer: a retrospective survey by the Sankai
Gynecology Study Group. 2013;18(6):1107-13.
22. Sakai K, Kajiyama H, Umezu T, Shibata K, Mizuno M, Suzuki S, et al.
Is there any association between retroperitoneal lymphadenectomy and
survival benefit in advanced stage epithelial ovarian carcinoma
patients? 2012;38(7):1018-23.
23. Chang S-J, Bristow RE, Ryu H-SJGo. Prognostic significance of
systematic lymphadenectomy as part of primary debulking surgery in
patients with advanced ovarian cancer. 2012;126(3):381-6.
24. Abe A, Furumoto H, Irahara M, Ino H, Kamada M, Naka O, et al. The
impact of systematic para‐aortic and pelvic lymphadenectomy on survival
in patients with optimally debulked ovarian cancer. 2010;36(5):1023-30.
25. Du Bois A, Reuss A, Harter P, Pujade-Lauraine E, Ray-Coquard I,
Pfisterer JJJoco. Potential role of lymphadenectomy in advanced ovarian
cancer: a combined exploratory analysis of three prospectively
randomized phase III multicenter trials. 2010;28(10):1733-9.
26. Scarabelli C, Gallo A, Visentin M, Canzonieri V, Carbone A, Zarrelli
AJIJoGC. Systematic pelvic and para‐aortic lymphadenectomy in advanced
ovarian cancer patients with no residual intraperitoneal disease.
1997;7(1):18-26.
27. Scarabelli C, Gallo A, Zarrelli A, Visentin C, Campagnutta EJGo.
Systematic pelvic and para-aortic lymphadenectomy during cytoreductive
surgery in advanced ovarian cancer: potential benefit on survival.
1995;56(3):328-37.
28. Aletti GD, Dowdy S, Podratz KC, Cliby WAJAjoo, gynecology. Role of
lymphadenectomy in the management of grossly apparent advanced stage
epithelial ovarian cancer. 2006;195(6):1862-8.
29. Ercelep O, Ozcelik M, Gumus MJCpic. Association of lymphadenectomy
and survival in epithelial ovarian cancer. 2019;43(2):151-9.
30. Gmyrek LJ, Jonska-Gmyrek J, Sobiczewski P, Panek G, Bidzinski MJOl.
Evaluation of intraoperative and postoperative complications related to
lymphadenectomy in ovarian cancer patients. 2011;2(3):537-41.
31. Ho C-M, Chien T-Y, Shih B-Y, Huang S-HJGo. Evaluation of complete
surgical staging with pelvic and para-aortic lymphadenectomy and
paclitaxel plus carboplatin chemotherapy for improvement of survival in
stage I ovarian clear cell carcinoma. 2003;88(3):394-9.
32. Maggioni A, Panici PB, Dell’Anna T, Landoni F, Lissoni A, Pellegrino
A, et al. Randomised study of systematic lymphadenectomy in patients
with epithelial ovarian cancer macroscopically confined to the pelvis.
2006;95(6):699-704.
33. Panici PB, Maggioni A, Hacker N, Landoni F, Ackermann S, Campagnutta
E, et al. Systematic aortic and pelvic lymphadenectomy versus resection
of bulky nodes only in optimally debulked advanced ovarian cancer: a
randomized clinical trial. 2005;97(8):560-6.
34. Ho CM, Chien TY, Shih BY, Huang SH. Evaluation of complete surgical
staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus
carboplatin chemotherapy for improvement of survival in stage I ovarian
clear cell carcinoma. Gynecologic oncology. 2003;88(3):394‐9.
35. Siegel R, Naishadham DJCCjC. jemal A: Cancer statistics, 2013.
2013;63:11-30.
36. Hunn J, Rodriguez GCJCo, gynecology. Ovarian cancer: etiology, risk
factors, and epidemiology. 2012;55(1):3-23.
37. Trimbos B, Timmers P, Pecorelli S, Coens C, Ven K, Van der Burg M,
et al. Surgical staging and treatment of early ovarian cancer: long-term
analysis from a randomized trial. 2010;102(13):982-7.
38. Holschneider CH, Berek JS, editors. Ovarian cancer: epidemiology,
biology, and prognostic factors. Seminars in surgical oncology; 2000:
Wiley Online Library.
39. Eisenkop SM, Spirtos NMJGo. The clinical significance of occult
macroscopically positive retroperitoneal nodes in patients with
epithelial ovarian cancer. 2001;82(1):143-9.
40. Morice P, Joulie F, Rey A, Atallah D, Camatte S, Pautier P, et al.
Are nodal metastases in ovarian cancer chemoresistant lesions? Analysis
of nodal involvement in 105 patients treated with preoperative
chemotherapy. 2004;25(2):169-74.
41. Berek JSJIJoGC. Lymph node-positive stage IIIC ovarian cancer: a
separate entity? 2009;19(Suppl 2).
42. Kim HS, Ju W, Jee BC, Kim YB, Park NH, Song YS, et al. Systematic
lymphadenectomy for survival in epithelial ovarian cancer: a
meta-analysis. 2010;20(4).
43. Gao J, Yang X, Zhang YJJjoco. Systematic lymphadenectomy in the
treatment of epithelial ovarian cancer: a meta-analysis of multiple
epidemiology studies. 2015;45(1):49-60.
44. Zhou J, Shan G, Chen YJJjoco. The effect of lymphadenectomy on
survival and recurrence in patients with ovarian cancer: a systematic
review and meta-analysis. 2016;46(8):718-26.
45. Lin Q, Liu W, Xu S, Li J, Tong JJJoOR. The value of systematic
lymphadenectomy during debulking surgery in the treatment of ovarian
cancer: a meta-analysis of randomized controlled trials. 2020;13:1-8.
46. Xu D, Xue J, Rozan R, Li LJAopm. The role systematic lymphadenectomy
plays in determining the survival outcome for advanced ovarian cancer
patients: a meta-analysis. 2020.
47. Wang Y, Ren F, Song Z, Wang X, Zhang C, Ouyang LJFio. Prognostic
significance of systematic lymphadenectomy in patients with optimally
debulked advanced ovarian cancer: a meta-analysis. 2020;10:86.
48. Qin M, Jin Y, Ma L, Zhang Y-Y, Pan L-YJO. The role of neoadjuvant
chemotherapy followed by interval debulking surgery in advanced ovarian
cancer: a systematic review and meta-analysis of randomized controlled
trials and observational studies. 2018;9(9):8614.